Ask about this productRelated genes to: RPP40 antibody
- Gene:
- RPP40 NIH gene
- Name:
- ribonuclease P/MRP subunit p40
- Previous symbol:
- RNASEP1
- Synonyms:
- bA428J1.3
- Chromosome:
- 6p25.1
- Locus Type:
- gene with protein product
- Date approved:
- 2003-04-30
- Date modifiied:
- 2016-04-05
Related products to: RPP40 antibody
Related articles to: RPP40 antibody
- Hepatocellular carcinoma (HCC) represents a major global health burden. While the ribonucleoprotein complex subunit RPP40 plays a critical role in precursor tRNA processing and has demonstrated prognostic value in several cancer types, its specific function and underlying mechanisms in HCC pathogenesis remain poorly understood. - Source: PubMed
Publication date: 2026/07/06
Huang Li-NaZhang Cheng-HuiCheng GangChen FangTao TaoZhang XianHuang MengZhang BinChen Juan - BACKGROUND: Ribonuclease P/MRP subunit p40 (RPP40) is a core component of the RNase P/MRP ribonucleoprotein complex, playing a central role in RNA processing. However, its systematic characteristics, clinical significance, and functional mechanisms at the pan-cancer level remain unclear. METHODS: We systematically characterized the pan-cancer expression profile and prognostic value of RPP40 using multi-omics approaches, including pan-cancer expression profiling, CRISPR screening, single-cell RNA sequencing, immunohistochemistry, proteomics, and multi-level survival analyses. We further examined correlations between RPP40 expression and diverse clinical indicators, including tumor stage, treatment response, immune subtype, and demographic characteristics. RESULTS: RPP40 expression was significantly upregulated in most cancers and their subtypes, and it was identified as a broadly essential gene for cancer cell survival. High RPP40 expression was significantly associated with advanced tumor stage and poor prognosis, serving as an independent risk factor for overall survival and progression-free survival across multiple independent cohorts. Our multidimensional analytical framework further revealed significant associations between RPP40 expression and various features, including pathological stage, major tumor subtypes, and smoking history. Functionally, RPP40 likely promotes tumor proliferation by activating cell cycle pathways, and its expression displays strong cell cycle dependency. CONCLUSION: This study systematically elucidates the oncogenic role of RPP40 across cancers, establishing it as a novel and translationally promising pan-cancer prognostic biomarker and a potential therapeutic target. The “multi-level clinical–molecular integrative analysis” framework developed herein provides foundational evidence and data support for subsequent precision therapeutic strategies targeting RPP40. - Source: PubMed
Publication date: 2026/04/03
Man Yu-NanHe Mao-Lin - Hepatocellular carcinoma (HCC) is one of the most prevalent malignant tumors worldwide. The intricate molecular processes that drive the development and advancement of HCC are still not entirely clear. Recent studies have implicated the 11 protein subunits of ribonuclease P (POP1, POP4, POP5, POP7, RPP14, RPP21, RPP25, two copies of RPP30, RPP38, and RPP40) in various cancers, yet their specific roles in HCC require further clarification. In this study, we found that elevated levels of ribonuclease P/MRP Subunit P40 (RPP40) are associated with a worse outcome for HCC patients. RPP40 promotes proliferation, migration and invasion in HCC cells. Our findings reveal that RPP40 can coordinate the transcription of ribosomal RNA and the expression of ribosomal genes, thereby promoting the malignancy of HCC. Our findings provide preliminary evidence that RPP40 could be considered a candidate target for HCC therapy. - Source: PubMed
Publication date: 2025/06/13
Tian BinXia XinMa XingyuYang Zhi-ZhiDong Yi-MingLiao Jian-YouDeng YawenZhu Liwen - Low-grade glioma (LGG) is a grade II-III glioma accompanied by distinct clinical and molecular characteristics and the studies related to its prognosis are still unclear. The objective of this study is to explore the involvement of mitochondrial-related genes SLBP, COMMD7, LSM4, TOMM34, RPP40, FKBP1A, ARPC1A, and TBCA for the prognosis of LGG. We detected differences in the expression of some of the genes by analyzing the bioinformatics dataset and combining it with RT-PCR experiments. Subsequently, a nomogram was constructed and validated for the clinical relevance of risk factors such as age, WHO grade, IDH mutation status, Ch.1p19q co-deletion status, and high and low expression of ARPC1A to predict the 1-, 3-, 5-year overall survival and prognostic relevance of ARPC1A. Gene set enrichment analysis was performed for the relevant datasets pertinent to the expression of ARPC1A to elucidate the cancer-promoting pathways involved in the LGG through KEGG and GO analysis. Transfection assays, CCK-8 assays, and flow cytometry were used to determine the proliferation rate, and apoptosis rate of the HS683 and SW1783 cell lines respectively. Western blotting was used to examine the involvement of the cancer-promoting activity of ARPC1A through MAPK signaling. In this study, the prognostic value of ARPC1A in LGG was found by bioinformatics analysis combined with experimental approach analysis and may be a significant independent risk factor. ARPC1A fosters a higher LGG proliferation rate that may control the MAP kinase signaling and could be a prominent biomarker for LGG. Future studies are warranted to explore its clinical implications. - Source: PubMed
Publication date: 2024/06/19
Dai JingyuanGao JiahuiDong Hongchao - Ribonuclease P/MRP Subunit P40 (RPP40), a component of ribonuclease P and multimeric ribonuclease P complex, was reported as one of the promoting factors for the chemoresistance of acute myeloid leukemia and a recurrence predictor of early-stage triple-negative breast cancer. However, the functional role of RPP40 in uterine corpus endometrial carcinoma (UCEC) is unclear. In this study, comprehensive bioinformatic analyses were conducted to explore the predictive role of RPP40 on UCEC diagnosis and prognosis, as well as the underlying mechanism. Differential analyses of multiple databases showed that both messenger RNA (mRNA) and the protein expression of RPP40 were significantly upregulated in UCEC tumor tissues. Furthermore, the RPP40 mRNA expression level was significantly correlated with the clinicopathological characteristics of UCEC patients, including the clinical stage, primary therapy outcome, histological type, histologic grade, overall survival event, disease-specific survival event, and progression-free interval event. Receiver operating characteristic (ROC) analysis showed that RPP40 was a reliable predictor for UCEC diagnosis with an area under the curve (AUC) of 0.775, a sensitivity of 0.829, and a specificity of 0.719. Kaplan-Meier, Cox regression, and nomogram analyses showed that high RPP40 expression was an independent prognostic factor for the 1-year, 3-year, and 5-year survival of UCEC patients. In addition, the enrichment analysis of RPP40-associated differentially expressed genes and correlation analyses showed that the expression of RPP40 was correlated with the regulation of extracellular matrix and immune cell infiltration. In conclusion, the upregulation of RPP40 is significantly correlated with the poor survival and tumor microenvironment of UCEC, suggesting that RPP40 is a promising biomarker of poor prognosis and a potential target of chemotherapy or immunotherapy in UCEC. - Source: PubMed
Publication date: 2022/08/24
Tang JianmingTian XiaoliMin JieHu MingHong Li